Barclays PLC Prothena Corp Public LTD CO Transaction History

Barclays PLC

  • $377 Billion
  • Q3 2024

A detailed history of Barclays PLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Barclays PLC holds 95,222 shares of PRTA stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
95,222
Previous 95,222 -0.0%
Holding current value
$1.47 Million
Previous $1.59 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024
BUY
$16.73 - $24.79 $835,094 - $1.24 Million
49,916 Added 110.18%
95,222 $1.59 Million
Q2 2024

Aug 14, 2024
SELL
$19.54 - $26.15 $254,528 - $340,629
-13,026 Reduced 22.33%
45,306 $935,000
Q1 2024

May 15, 2024
SELL
$24.75 - $40.66 $2.09 Million - $3.43 Million
-84,275 Reduced 59.1%
58,332 $1.44 Million
Q4 2023

Feb 15, 2024
BUY
$32.31 - $52.32 $1.83 Million - $2.96 Million
56,572 Added 65.75%
142,607 $5.18 Million
Q3 2023

Nov 07, 2023
BUY
$47.3 - $70.6 $861,947 - $1.29 Million
18,223 Added 26.87%
86,035 $4.15 Million
Q2 2023

Aug 03, 2023
BUY
$48.26 - $78.59 $154,818 - $252,116
3,208 Added 4.97%
67,812 $4.63 Million
Q1 2023

May 04, 2023
SELL
$46.97 - $58.27 $692,102 - $858,608
-14,735 Reduced 18.57%
64,604 $3.13 Million
Q4 2022

Feb 13, 2023
BUY
$52.05 - $65.0 $586,967 - $733,005
11,277 Added 16.57%
79,339 $4.78 Million
Q3 2022

Nov 03, 2022
BUY
$25.16 - $60.63 $1.67 Million - $4.02 Million
66,281 Added 3721.56%
68,062 $4.13 Million
Q2 2022

Aug 12, 2022
SELL
$22.73 - $39.98 $139,766 - $245,837
-6,149 Reduced 77.54%
1,781 $48,000
Q1 2022

May 16, 2022
SELL
$30.27 - $49.22 $1.24 Million - $2.02 Million
-40,950 Reduced 83.78%
7,930 $291,000
Q4 2021

Feb 14, 2022
BUY
$42.11 - $73.26 $1.3 Million - $2.26 Million
30,844 Added 171.01%
48,880 $2.42 Million
Q3 2021

Nov 09, 2021
BUY
$48.2 - $78.89 $466,383 - $763,339
9,676 Added 115.74%
18,036 $1.28 Million
Q2 2021

Aug 13, 2021
SELL
$21.63 - $57.65 $457,193 - $1.22 Million
-21,137 Reduced 71.66%
8,360 $429,000
Q1 2021

May 13, 2021
BUY
$11.0 - $28.24 $135,168 - $347,013
12,288 Added 71.4%
29,497 $740,000
Q4 2020

Feb 11, 2021
SELL
$10.12 - $13.94 $42,504 - $58,548
-4,200 Reduced 19.62%
17,209 $206,000
Q3 2020

Nov 12, 2020
SELL
$9.93 - $13.47 $67,097 - $91,016
-6,757 Reduced 23.99%
21,409 $215,000
Q2 2020

Aug 12, 2020
SELL
$9.56 - $12.51 $88,735 - $116,117
-9,282 Reduced 24.79%
28,166 $294,000
Q1 2020

May 13, 2020
SELL
$7.54 - $15.77 $349,840 - $731,696
-46,398 Reduced 55.34%
37,448 $401,000
Q4 2019

Feb 10, 2020
BUY
$7.48 - $17.01 $254,649 - $579,088
34,044 Added 68.36%
83,846 $1.33 Million
Q3 2019

Nov 14, 2019
BUY
$6.89 - $10.45 $48,119 - $72,982
6,984 Added 16.31%
49,802 $391,000
Q2 2019

Aug 14, 2019
BUY
$8.85 - $12.49 $46,391 - $65,472
5,242 Added 13.95%
42,818 $453,000
Q1 2019

May 15, 2019
BUY
$10.32 - $14.49 $111,817 - $156,999
10,835 Added 40.52%
37,576 $456,000
Q4 2018

Feb 14, 2019
SELL
$8.73 - $13.74 $45,361 - $71,393
-5,196 Reduced 16.27%
26,741 $275,000
Q3 2018

Nov 14, 2018
BUY
$12.7 - $15.79 $363,524 - $451,972
28,624 Added 863.99%
31,937 $418,000
Q2 2018

Aug 14, 2018
SELL
$10.99 - $44.21 $1.22 Million - $4.93 Million
-111,428 Reduced 97.11%
3,313 $48,000
Q1 2018

May 15, 2018
BUY
$27.95 - $45.04 $2.04 Million - $3.28 Million
72,866 Added 174.01%
114,741 $4.21 Million
Q4 2017

Feb 14, 2018
BUY
$35.44 - $63.76 $461,570 - $830,410
13,024 Added 45.14%
41,875 $1.57 Million
Q3 2017

Nov 14, 2017
BUY
$53.83 - $67.75 $1.55 Million - $1.95 Million
28,851
28,851 $1.87 Million

Others Institutions Holding PRTA

# of Institutions
186
Shares Held
42.8M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $726M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email